Aurobindo Pharma reported a consolidated net profit of ₹10,320.3 million for the quarter ended June 30, 2026, up 25.2% year-on-year from ₹8,242.0 million in Q1FY25. The Hyderabad-based generic drug manufacturer saw its total income from operations rise 16.3% to ₹91,503.5 million, reflecting sustained demand in key markets despite a challenging global regulatory environment.

The Board of Directors approved the unaudited financial results on August 5, 2026. The results were published in Business Standard and Nava Telangana on August 7, 2026, and filed with the National Stock Exchange of India Limited and BSE Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. K. Nithyananda Reddy, Vice Chairman & Managing Director, signed off on the results.

Consolidated Financial Performance

Consolidated profit before tax stood at ₹15,150.9 million, compared to ₹12,068.0 million in the same quarter last year. Earnings per share (basic and diluted) increased to ₹17.86 from ₹14.20 in Q1FY25. Total comprehensive income for the period was ₹9,851.6 million.

Standalone Results

On a standalone basis, Aurobindo Pharma posted a net profit of ₹7,372.2 million, up 31.9% from ₹5,591.3 million in Q1FY25. Standalone revenue from operations was ₹27,995.1 million, slightly lower than ₹28,481.7 million in the prior year period. Standalone EPS rose to ₹12.75 from ₹9.63.

What the Numbers Show

The divergence between consolidated and standalone revenue trends warrants attention. While consolidated revenue grew 16.3% year-on-year, standalone revenue contracted 1.7%. This suggests that growth is being driven primarily by subsidiaries or associates within the consolidated group, rather than the parent entity’s direct operations. Investors should monitor segment-wise disclosures in future filings to understand which geographies or business units are contributing most to this top-line expansion.

Aurobindo Pharma Limited has announced that its officials will participate in the Nuvama India Conference 2026, scheduled to take place from August 11 to 13, 2026. The engagement is designed to facilitate dialogue with investors and analysts through both in-person and group meetings across Singapore and Hong Kong. This participation underscores the company's commitment to maintaining transparent communication channels with its global investor base.

The conference sessions are scheduled to run from 09:00 AM to 06:00 PM (GMT +8) each day. Aurobindo Pharma emphasized that no unpublished price-sensitive information (UPSI) will be discussed during these interactions, ensuring compliance with regulatory standards regarding information symmetry.

Event Details

The specific logistics of the investor meeting are outlined below:

Regulatory Compliance

The company submitted this disclosure to the Listing Department of the National Stock Exchange of India Limited and the Corporate Relations Department of BSE Limited on August 6, 2026. The filing was signed by B. Adi Reddy, Company Secretary, affirming the accuracy of the schedule and the absence of UPSI dissemination.

Schedule Flexibility

Aurobindo Pharma noted that the schedule is subject to change due to exigencies on the part of either the investor or the company. Stakeholders are advised to monitor official communications for any updates regarding timing or location adjustments.